Zealand Pharma — November 2022
-
Godmorgen
-
Godmorgen
-
Zealand Pharma/Morgan Stanley: Kursmål løftes til 235 kr. fra 179 kr.
https://www.proinvestor.com/investornyt/897946/zealand-pharma-morgan-stanley-kursmal-loftes-til-235-kr-fra-179-kr -
Tirsdagens danske avisuddrag med SAS, Musk og tågede renteudsigter https://www.proinvestor.com/investornyt/897951/tirsdagens-danske-avisuddrag-med-sas-musk-og-tagede-renteudsigter
-
God formiddag:)
-
202 op 5% fab
-
op 39% i år. outstanding
-
Nu er det store kursfald fra 2021 elimineret
-
præcis
-
gentager: TAK
-
Fantastisk.
-
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
Press release – No. 7 / 2022Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
Results from the phase 2 clinical trial of GCGR/GLP-1R dual agonist BI 456906 showing bodyweight reductions of up to 9% after 16 weeks in people with type 2 diabetes to be presented
Four preclinical presentations highlighting effects of Zealand Pharma’s three wholly owned peptide therapeutic candidates (dapigluti
-
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting (inkl. link):
-
Zealand leverer vægttabsdata for middel under Boehringer-samarbejde https://www.proinvestor.com/investornyt
/898309/zealand-leverer-vaegttabsdata-for-middel-under-boehringer-samarbejde
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind